Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression

Matthew C. Solhjem, Brian J. Davis, Thomas M. Pisansky, Torrence M. Wilson, Lance A. Mynderse, David W. Hillman, Michael G. Herman, Bernard Francis King

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

PURPOSE: Limited duration neoadjuvant cytoreductive hormonal therapy (NHT) is used before the definitive radiotherapeutic management of prostate cancer to decrease target volume size and/or to decrease urinary obstructive symptoms. The purpose of this study is to examine the effect of NHT on prostate volume before permanent prostate brachytherapy (PPB) and on prostatic edema after PPB. METHODS AND MATERIALS: Between May 1998 and February 2004, 408 patients underwent PPB at our institution and provided research authorization for the use of their records. Of these, 122 (30%) underwent NHT. Of the 122, 78 (64%) underwent transrectal ultrasound before the start of NHT. Patients undergoing PPB who received NHT were compared with a similar non-NHT group (N = 286). Detailed measurements of prostate volume were performed by transrectal ultrasound before and after NHT, if applicable. In addition, intraoperative preimplantation transrectal ultrasound and postimplantation transrectal ultrasound were also performed. Postimplantation computed tomography was performed within 1 day of PPB. RESULTS: The mean duration of NHT was 4.0 ± 1.1 months (range, 1-8 months). The mean prostate volume before NHT was 63.3 ± 22.8 cc (range, 19-138 cc), and after NHT (before PPB), it was 41.6 ± 16.4 cc (18-98 cc). The median prostate volume decrease after NHT was 22.7 cc or 34.9%. There was no significant difference in the degree of postimplantation prostate edema, as measured by the postimplantation to preimplantation ratio (1.18 ± 0.05 [range, 0.8-1.9]) for the NHT group and 1.21 ± 0.03 (range, 0.8-1.9) for the non-NHT group (P = 0.5). CONCLUSIONS: Prostate volume decreased by approximately one third after 4 months of NHT. NHT did not affect the degree of post-PPB prostatic edema.

Original languageEnglish (US)
Pages (from-to)343-348
Number of pages6
JournalCancer Journal
Volume10
Issue number6
DOIs
StatePublished - Nov 2004

Fingerprint

Brachytherapy
Androgens
Prostate
Therapeutics
Group Psychotherapy
Edema
Prostatic Neoplasms
Tomography

Keywords

  • Brachytherapy
  • Neoadjuvant hormonal therapy
  • Prostate cancer
  • Prostate volume

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression. / Solhjem, Matthew C.; Davis, Brian J.; Pisansky, Thomas M.; Wilson, Torrence M.; Mynderse, Lance A.; Hillman, David W.; Herman, Michael G.; King, Bernard Francis.

In: Cancer Journal, Vol. 10, No. 6, 11.2004, p. 343-348.

Research output: Contribution to journalArticle

Solhjem, MC, Davis, BJ, Pisansky, TM, Wilson, TM, Mynderse, LA, Hillman, DW, Herman, MG & King, BF 2004, 'Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression', Cancer Journal, vol. 10, no. 6, pp. 343-348. https://doi.org/10.1097/00130404-200411000-00003
Solhjem, Matthew C. ; Davis, Brian J. ; Pisansky, Thomas M. ; Wilson, Torrence M. ; Mynderse, Lance A. ; Hillman, David W. ; Herman, Michael G. ; King, Bernard Francis. / Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression. In: Cancer Journal. 2004 ; Vol. 10, No. 6. pp. 343-348.
@article{d7ef91843e1142dd84cfdcd060d162d5,
title = "Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression",
abstract = "PURPOSE: Limited duration neoadjuvant cytoreductive hormonal therapy (NHT) is used before the definitive radiotherapeutic management of prostate cancer to decrease target volume size and/or to decrease urinary obstructive symptoms. The purpose of this study is to examine the effect of NHT on prostate volume before permanent prostate brachytherapy (PPB) and on prostatic edema after PPB. METHODS AND MATERIALS: Between May 1998 and February 2004, 408 patients underwent PPB at our institution and provided research authorization for the use of their records. Of these, 122 (30{\%}) underwent NHT. Of the 122, 78 (64{\%}) underwent transrectal ultrasound before the start of NHT. Patients undergoing PPB who received NHT were compared with a similar non-NHT group (N = 286). Detailed measurements of prostate volume were performed by transrectal ultrasound before and after NHT, if applicable. In addition, intraoperative preimplantation transrectal ultrasound and postimplantation transrectal ultrasound were also performed. Postimplantation computed tomography was performed within 1 day of PPB. RESULTS: The mean duration of NHT was 4.0 ± 1.1 months (range, 1-8 months). The mean prostate volume before NHT was 63.3 ± 22.8 cc (range, 19-138 cc), and after NHT (before PPB), it was 41.6 ± 16.4 cc (18-98 cc). The median prostate volume decrease after NHT was 22.7 cc or 34.9{\%}. There was no significant difference in the degree of postimplantation prostate edema, as measured by the postimplantation to preimplantation ratio (1.18 ± 0.05 [range, 0.8-1.9]) for the NHT group and 1.21 ± 0.03 (range, 0.8-1.9) for the non-NHT group (P = 0.5). CONCLUSIONS: Prostate volume decreased by approximately one third after 4 months of NHT. NHT did not affect the degree of post-PPB prostatic edema.",
keywords = "Brachytherapy, Neoadjuvant hormonal therapy, Prostate cancer, Prostate volume",
author = "Solhjem, {Matthew C.} and Davis, {Brian J.} and Pisansky, {Thomas M.} and Wilson, {Torrence M.} and Mynderse, {Lance A.} and Hillman, {David W.} and Herman, {Michael G.} and King, {Bernard Francis}",
year = "2004",
month = "11",
doi = "10.1097/00130404-200411000-00003",
language = "English (US)",
volume = "10",
pages = "343--348",
journal = "Cancer Journal (United States)",
issn = "1528-9117",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "6",

}

TY - JOUR

T1 - Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression

AU - Solhjem, Matthew C.

AU - Davis, Brian J.

AU - Pisansky, Thomas M.

AU - Wilson, Torrence M.

AU - Mynderse, Lance A.

AU - Hillman, David W.

AU - Herman, Michael G.

AU - King, Bernard Francis

PY - 2004/11

Y1 - 2004/11

N2 - PURPOSE: Limited duration neoadjuvant cytoreductive hormonal therapy (NHT) is used before the definitive radiotherapeutic management of prostate cancer to decrease target volume size and/or to decrease urinary obstructive symptoms. The purpose of this study is to examine the effect of NHT on prostate volume before permanent prostate brachytherapy (PPB) and on prostatic edema after PPB. METHODS AND MATERIALS: Between May 1998 and February 2004, 408 patients underwent PPB at our institution and provided research authorization for the use of their records. Of these, 122 (30%) underwent NHT. Of the 122, 78 (64%) underwent transrectal ultrasound before the start of NHT. Patients undergoing PPB who received NHT were compared with a similar non-NHT group (N = 286). Detailed measurements of prostate volume were performed by transrectal ultrasound before and after NHT, if applicable. In addition, intraoperative preimplantation transrectal ultrasound and postimplantation transrectal ultrasound were also performed. Postimplantation computed tomography was performed within 1 day of PPB. RESULTS: The mean duration of NHT was 4.0 ± 1.1 months (range, 1-8 months). The mean prostate volume before NHT was 63.3 ± 22.8 cc (range, 19-138 cc), and after NHT (before PPB), it was 41.6 ± 16.4 cc (18-98 cc). The median prostate volume decrease after NHT was 22.7 cc or 34.9%. There was no significant difference in the degree of postimplantation prostate edema, as measured by the postimplantation to preimplantation ratio (1.18 ± 0.05 [range, 0.8-1.9]) for the NHT group and 1.21 ± 0.03 (range, 0.8-1.9) for the non-NHT group (P = 0.5). CONCLUSIONS: Prostate volume decreased by approximately one third after 4 months of NHT. NHT did not affect the degree of post-PPB prostatic edema.

AB - PURPOSE: Limited duration neoadjuvant cytoreductive hormonal therapy (NHT) is used before the definitive radiotherapeutic management of prostate cancer to decrease target volume size and/or to decrease urinary obstructive symptoms. The purpose of this study is to examine the effect of NHT on prostate volume before permanent prostate brachytherapy (PPB) and on prostatic edema after PPB. METHODS AND MATERIALS: Between May 1998 and February 2004, 408 patients underwent PPB at our institution and provided research authorization for the use of their records. Of these, 122 (30%) underwent NHT. Of the 122, 78 (64%) underwent transrectal ultrasound before the start of NHT. Patients undergoing PPB who received NHT were compared with a similar non-NHT group (N = 286). Detailed measurements of prostate volume were performed by transrectal ultrasound before and after NHT, if applicable. In addition, intraoperative preimplantation transrectal ultrasound and postimplantation transrectal ultrasound were also performed. Postimplantation computed tomography was performed within 1 day of PPB. RESULTS: The mean duration of NHT was 4.0 ± 1.1 months (range, 1-8 months). The mean prostate volume before NHT was 63.3 ± 22.8 cc (range, 19-138 cc), and after NHT (before PPB), it was 41.6 ± 16.4 cc (18-98 cc). The median prostate volume decrease after NHT was 22.7 cc or 34.9%. There was no significant difference in the degree of postimplantation prostate edema, as measured by the postimplantation to preimplantation ratio (1.18 ± 0.05 [range, 0.8-1.9]) for the NHT group and 1.21 ± 0.03 (range, 0.8-1.9) for the non-NHT group (P = 0.5). CONCLUSIONS: Prostate volume decreased by approximately one third after 4 months of NHT. NHT did not affect the degree of post-PPB prostatic edema.

KW - Brachytherapy

KW - Neoadjuvant hormonal therapy

KW - Prostate cancer

KW - Prostate volume

UR - http://www.scopus.com/inward/record.url?scp=15744390321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15744390321&partnerID=8YFLogxK

U2 - 10.1097/00130404-200411000-00003

DO - 10.1097/00130404-200411000-00003

M3 - Article

C2 - 15701265

AN - SCOPUS:15744390321

VL - 10

SP - 343

EP - 348

JO - Cancer Journal (United States)

JF - Cancer Journal (United States)

SN - 1528-9117

IS - 6

ER -